Evidence map›Paper›PMID 31134566›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2019

Designing Cell-Permeable Macrocyclic Peptides.

George Appiah Kubi, Patrick G Dougherty, Dehua Pei

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
  4. Umpolung AlaAngewandte Chemie (International ed. in English) · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

George Appiah KubiDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.
Patrick G DoughertyDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.
Dehua PeiDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA. pei.3@osu.edu.
The Ohio State University · US

Funding

Development of Cell-Permeable Peptides and ProteinsR35GM122459 · NIGMS · OHIO STATE UNIVERSITY · PI Dehua Pei · 2017 to 2026
$5.1M
NIGMS NIH HHS R35 GM122459
6 · The paper itself

Abstract

Peptides provide an attractive modality for targeting challenging drug targets such as intracellular protein-protein interactions. Unfortunately, peptides are generally impermeable to the cell membrane and inherently susceptible to proteolytic degradation in vivo. Macrocyclization of peptides greatly increases their proteolytic stability and in some cases the cell-penetrating activity. Conjugation of peptidyl cargoes to cyclic cell-penetrating peptides has resulted in potent, cell-permeable, and metabolically stable macrocyclic peptides against intracellular protein targets. Proper conjugation/integration of a peptidyl cargo with a cyclic cell-penetrating peptide is critical to retain the activity of each component and generate a biologically active macrocyclic peptide. This chapter describes the different conjugation strategies that have been developed (including endocyclic, bicyclic, and reversible cyclization methods) and the detailed protocols for their preparation.

Indexed as

Amino Acid SequenceCell Membrane PermeabilityCell-Penetrating PeptidesCyclizationDrug Delivery SystemsHeLa CellsHumansPeptides, CyclicProteolysisCell-Penetrating PeptidesPeptides, CyclicBicyclic peptidesCyclic cell-penetrating peptidesCyclic peptidesProtein-protein interactionReversible cyclization

Identifiers

PMID31134566
PMCPMC7277897
OpenAlexW2947842456

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.